ArticleVirchows Archiv : an international journal of pathology2026
Low-grade fibromyxoid sarcoma in abdominopelvic and retroperitoneal locations: a clinicopathologic analysis of 26 cases and a review of the literature.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Low-grade fibromyxoid sarcoma (LGFMS) is a rare, slow-growing deceptively bland-looking fibroblastic sarcoma that usually develops in the deep soft tissues of the extremities. Development of the tumor in the abdomen, pelvis, and retroperitoneum is extremely rare. We analyzed 26 cases of LGFMS originating at these sites. The patients age ranged from 5 to 75 years (median, 39) with a slight female predominance (54%). Most tumors were located in the abdominal wall/abdomen or peritoneal tissues (n = 11; 42%), followed by the intestinal wall/mesentery (n = 7; 27%), pelvis (n = 4; 15%), retroperitoneum (n = 3; 11%) and the perirectal perineum (n = 1; 4%). Median tumor size was 10 cm (range, 1.9-68). Histologically, tumors were characterized by spindle cells with mild-to-moderate nuclear atypia arranged into short fascicles and whorling pattern within alternating variably myxoid to collagenous stroma rich in arcuate vessels with perivascular hyalinization. Eight tumors (31%) showed areas of sclerosing epithelioid fibrosarcoma (SEF), hence qualifying as hybrid LGFMS/SEF. Large collagen rosettes were observed in 8 tumors (31%). All 26 tumors (100%) were immunohistochemically diffusely positive for MUC4. FUS or EWSR1 gene rearrangements were identified in 9 of 9 (100%) tumors tested. One of 17 tumors showed variable nuclear Betacatenin reactivity (this case harbored EWSR1::CREB3L1 fusion). Of 15 patients with follow-up data (range, 6-84 months; median, 28.5), 2 (13%) died of disease, 3 (20%) developed metastases, and 2 (13%) had local tumor recurrence. In total, 7 (47%) patients experienced disease progression. Eight (53%) patients were disease-free at 5-84 months follow-up (median, 45). LGFMSs at these rare sites are similar to their extremity counterparts but likely peruse a more aggressive clinical course with adverse events being noted in half of patients at a median follow-up of 45 months, suggesting a possibly more unfavorable outcome at long-term.
Indexed as
Identifiers
42501102What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.